3 January, 2011
Download Brochure
   
   
   
   
   
 
Email Updates
 
   
   
   
   
   

Presentations

 

Gulzar Sandhu, VP Global Licensing, Bayer Healthcare and Roger Harrison, CBO, Algeta

Deal Case Study: Bayer/Algeta: A Win-Win Deal Around A Cancer Drug With Block-Buster Potential

    

Christoph Sarry, Global Alliance Director, Roche and Ian Massey, CEO, Synosia

Deal Case Study: Roche/ Synosia – Creating A Broad Partnership To Develop Promising Drug Candidates

 


    

Jane Devereux, Senior Director, Corporate Licensing Team, Merck & Co. Inc.

Deal Case Study: Merck/Schering Plough – Discussing The Strategic Benefits Of Merging Two Commercial Pipelines And Putting In Place Plans For Effective Integration

    

Ian Nicholson, CEO, Chroma Therapeutics and Shelagh Wilson, Vice President, Head of CEEDD, GSK

Deal Case Study: GSK/Chroma – Using ESM Technology To Drive A Multi-Level Relationship


    

Onno van de Stolpe, CEO, Galapagos

Funding Case Study: How Galapagos Leveraged Its Alliance Strategy To Capitalise on Its Technology and Build a Promising Pipeline


    

Kees Lucas, Managing Director, Life Science Consultancy

Is A Shortage Of Late-Stage Products Driving Growth In Pre-Clinical Deals? How Can This Be Leveraged To Your Advantage?

    

Christopher Barrat, Director, Greystone Consulting

Bringing Cultures Together – In The World Of Partnering, Acquisitions And Mergers, How Can You Get The Most From Bringing Different Cultures Together. What Works And What Doesn’t!

    

Dr. Peter Neubeck, Principal, TVM Capital

Early-Stage Deals, A Win-Win For Big Pharma And Founders – The VC Perspective

    

Lee Holmes, Senior Manager Business Development, BTG and Andrew Hindman, Vice President, Corporate Development, Onyx Pharmaceuticals

Case Study: BTG/Onyx – Identifying The Potential In Novel Cancer Compounds Putting In Place A Deal To Deliver Consistent Results


    

Yetunde Taiwo, Senior Director, Global External R & D, Eli Lilly, Dr. Adam Houghton, Advisor, Global External Research & Development, Eli Lilly & Onno van de Stolpe, CEO, Galapagos

Deal Case Study: Eli Lilly/Galapagos – Identifying The Drivers For An Early-Stage Deal And Building A Partnership To Support Successful Development